lifestyle.thedishh.com

Author: Faron Pharmaceuticals

CORRECTION: Faron Pharmaceuticals Ltd’s Annual Report 2025 published

March 4, 2026
Faron’s Financial Statements Release 1 January to 31 December 2025

March 4, 2026
Faron Pharmaceuticals Ltd’s Annual Report 2025 Published

March 4, 2026
Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting

March 2, 2026
Faron and City of Hope in Process of Developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS

March 2, 2026
Faron’s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026

February 23, 2026
Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML

February 19, 2026
Faron Pharmaceuticals Ltd: Notice To The Extraordinary General Meeting

February 9, 2026
New Review Published in Immunotherapy Highlights the Potential for Clever-1 Inhibition with bexmarilimab to Become the Cornerstone of Next-Generation, Multi-Indication Cancer Immunotherapy

January 29, 2026
Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma

January 27, 2026